Compare Ascendis Pharma A/S (ASND) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Kohl's Corporation — how do they compare? Ascendis Pharma A/S trades at $256 (market cap $16.67B), while Kohl's Corporation trades at $19.17 (market cap $2.10B). The key difference: Ascendis Pharma A/S is far larger — about 7.9× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KSS | |
|---|---|---|
Market Cap | $16.67B | $2.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $24.71 |
52-Week Low | $189.74 | $11.72 |
Enterprise Value | $17.04B | $8.20B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Kohl's (KSS) trades at $18.96, down 0.42% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows low valuation multiples (P/E of 7.77, P/S of 0.14) amid declining revenue, which fell to $16.22B in 2025. Recent Q1 2026 earnings beat expectations, and the company announced a $0.13 dividend for June 2026, alongside leadership changes including a new COO appointment in September 2026.
The outlook is mixed: low valuations and earnings beats offer value, but persistent sales declines and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility. Investors should weigh cost-cutting progress against macroeconomic headwinds in retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
